AU Pharmaceuticals, Inc. v. Whitner (In Re Whitner)

179 B.R. 699, 1995 Bankr. LEXIS 403, 1995 WL 140155
CourtUnited States Bankruptcy Court, E.D. Oklahoma
DecidedMarch 27, 1995
Docket19-80101
StatusPublished
Cited by9 cases

This text of 179 B.R. 699 (AU Pharmaceuticals, Inc. v. Whitner (In Re Whitner)) is published on Counsel Stack Legal Research, covering United States Bankruptcy Court, E.D. Oklahoma primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
AU Pharmaceuticals, Inc. v. Whitner (In Re Whitner), 179 B.R. 699, 1995 Bankr. LEXIS 403, 1995 WL 140155 (Okla. 1995).

Opinion

ORDER

TOM R. CORNISH, Bankruptcy Judge.

On this 27th day of March, 1995, the Motions for Summary Judgment of the Plaintiffs and Defendant came before this Court for consideration.

After a review of the above-referenced pleadings, this Court does hereby enter the following findings and conclusions in conformity with Rule 7052, Fed.R.Bankr.P., in this core proceeding:

FINDINGS OF FACT

1. On or about December 27, 1991, the Plaintiffs obtained a judgment in the United States District Court for the Eastern District of Texas against the Defendant, William L. Whitner, for trademark infringement.

2. This Court adopts the statement of facts of the Fifth Circuit in affirming the judgment entered in the United States District Court as follows:

In 1988, Jeff Ivy and Curtis Payne developed a topical analgesic product apparently unique in its use of gold as an ingredient. Ivy and Payne licensed their product to Associated Independent Marketers Incorporated of America (AIM), a company of which they were principals, which market *701 ed it under the brand name “Aurum.” Initially, GDMI, Inc. manufactured the product for AIM. When GDMI’s services proved inadequate, AIM entered into negotiations, subject to a confidentiality agreement, with John Beasley and Rita Gates of SCL. The negotiations culminated in an agreement under which SCL produced Au-rum for AIM. Desirous of distributing Aurum as an over-the-counter drug, AIM, upon advice of SCL, made slight changes in its formula to comply with the requirements of the Food and Drug Administration.
In October, 1989, Frank Trent and Don Rhodes resigned from the AIM board of directors and began their own venture distributing gold-based lotions. They purchased MaximHealth, Inc., an AIM subsidiary, acquired a sublicense from AIM to distribute Aurum, and negotiated a trademark license with AIM to distribute Au-rum under the name “MaximRelief.” SCL manufactured the product for both AIM and MaximHealth. Trent and Rhodes retained the distribution services of William Whitner and WSI for the MaximHealth product.
In December 1989, AIM filed a petition under Chapter 11 of the bankruptcy code. The bankruptcy court approved a sale of substantially all of AIM’s assets to AU Pharmaceuticals, Inc. (AUP), another company operated by Ivy and Payne. During the pendency of the bankruptcy proceedings, MaximHealth unilaterally terminated its licensing agreements with AIM, but continued to market the product. Sometime before this termination, and without informing AIM or AUP, SCL developed a new gold-based analgesic product called RG2-85. 1 SCL licensed RG2-85 to Max-imHealth, who distributed it through Whit-ner and WSI, continuing to use the “Max-imRelief’ name.
In November 1990, AIM initiated an adversary proceeding in the bankruptcy court against Trent, Rhodes, and Maxim-Health. AUP intervened, Amendments to the initial complaint stated claims against SCL, Whitner, WSI, and NAS. AIM and AUP sought recovery for misappropriation of trade secrets and conspiracy to misappropriate trade secrets by all defendants; trademark infringement and unfair competition by all defendants except NAS; breach of confidentiality agreement by SCL; breach of fiduciary duty by Trent, Rhodes, MaximHealth, and SCL; business disparagement by Whitner and WSI; and tortious interference with prospective contractual relations by WSI.

3. Before trial, AIM and AUP settled with Trent, Rhodes, and MaximHealth. After a six-day trial, the district court granted judgment as a matter of law against SCL as to liability on all claims and against Whitner and WSI as to liability for trademark infringement. The court granted judgment as a matter of law for Whitner and WSI on plaintiffs’ unfair competition, business disparagement, and tortious interference with prospective contractual relations claims. The Plaintiffs obtained a jury verdict against the Defendant in the amount of $1,000 for compensatory damages and $1,000 in punitive damages for misappropriation of trade secrets. The- Court, in addition to the jury verdict, ordered Whitner to pay part of the costs and attorneys’ fees.

4. The District Court’s jury instruction noted that “[pjunitive damages may be awarded for trade secret misappropriation and for breach of fiduciary duty. The Court has found a breach and misappropriation as it relates to Skin Care. You [the jury] have to make the decision as it relates to Whitner. You [the jury] may award punitive damages if the Defendants’ conduct was wrongful, intentional and without just cause or excuse.” Trial Transcript at 1071.

5. The Verdict Form filed in the District Court found that William Whitner, Whitner Sales, -Inc. and North American Sales, Inc. had misappropriated a trade secret belonging to AIM American or AU Pharmaceuticals.

CONCLUSIONS OF LAW

A. This court has jurisdiction pursuant to 28 U.S.C. §§ 1334, 151 and 157. This *702 is a core proceeding pursuant to 28 U.S.C. § 157(b)(2)(I).

B. The United States Supreme Court in Grogan v. Garner, 498 U.S. 279, 111 S.Ct. 654, 112 L.Ed.2d 755 (1991) held that bankruptcy courts in appropriate circumstances may give collateral estoppel effect to trial court decisions. Further, the Grogan court pronounced that the creditor need only prove by a preponderance of the evidence that the debt qualifies for the exception to discharge.

For collateral estoppel to apply, the Court must find:’

(1) the issue sought to be precluded is the same as that involved in the prior state court action;
(2) the issue was actually litigated by the parties in the prior action; and
(3) the state court’s determination of the issue was necessary to the resulting final and valid judgment.

In re Wallace, 840 F.2d 762, 764-65 (10th Cir.1988).

C. Section 523(a)(6) of the Bankruptcy Code provides that a discharge under Section 727 does not discharge an individual from “any debt for willful and malicious injury by the debtor to another entity or to the property of another entity.” A “willful and malicious injury” within the meaning of Section 523(a)(6) means “a wrongful act, intentionally, done without just cause or excuse.” In re Springer, 85 B.R. 634, 635 (Bankr.S.D.Fla.1988) (citations omitted).

D. The Tenth Circuit in In re Pasek,

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Washington v. Abreu
N.D. Georgia, 2021
Partners for Health & Home, L.P. v. Seung Wee Yang
488 B.R. 109 (C.D. California, 2012)
Suarez v. Barrett (In Re Suarez)
400 B.R. 732 (Ninth Circuit, 2009)
Glucona America, Inc. v. Ardisson (In Re Ardisson)
272 B.R. 346 (N.D. Illinois, 2001)
Bundy American Corp. v. Blankfort (In Re Blankfort)
217 B.R. 138 (S.D. New York, 1998)
Rupert v. Krautheimer (In Re Krautheimer)
210 B.R. 37 (S.D. New York, 1997)
Rowe Oil, Inc. v. McCoy (In Re McCoy)
189 B.R. 129 (N.D. Ohio, 1995)

Cite This Page — Counsel Stack

Bluebook (online)
179 B.R. 699, 1995 Bankr. LEXIS 403, 1995 WL 140155, Counsel Stack Legal Research, https://law.counselstack.com/opinion/au-pharmaceuticals-inc-v-whitner-in-re-whitner-okeb-1995.